---
title: "Needham Reaffirms Their Buy Rating on Globus Medical (GMED)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285711876.md"
description: "Needham analyst David Saxon has reaffirmed a Buy rating on Globus Medical (GMED) with a price target of $117.00. The analyst consensus for Globus Medical is a Strong Buy, with an average price target of $112.20. Saxon focuses on the Healthcare sector and has an average return of -2.3% with a 31.63% success rate on his stock recommendations."
datetime: "2026-05-08T11:00:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285711876.md)
  - [en](https://longbridge.com/en/news/285711876.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285711876.md)
---

# Needham Reaffirms Their Buy Rating on Globus Medical (GMED)

Needham analyst David Saxon reiterated a Buy rating on Globus Medical today and set a price target of $117.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Saxon covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA, Sight Sciences, and RxSight. According to TipRanks, Saxon has an average return of \-2.3% and a 31.63% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Globus Medical with a $112.20 average price target.

### Related Stocks

- [GMED.US](https://longbridge.com/en/quote/GMED.US.md)
- [XRAY.US](https://longbridge.com/en/quote/XRAY.US.md)
- [SGHT.US](https://longbridge.com/en/quote/SGHT.US.md)
- [RXST.US](https://longbridge.com/en/quote/RXST.US.md)

## Related News & Research

- [VIRGINIA RETIREMENT SYSTEMS ET Al Sells 17,300 Shares of Globus Medical, Inc. $GMED](https://longbridge.com/en/news/286670432.md)
- [Stifel Nicolaus Reaffirms Their Hold Rating on Globus Medical (GMED)](https://longbridge.com/en/news/285872659.md)
- [LifeSci Capital Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)](https://longbridge.com/en/news/286649191.md)
- [LifeSci Capital Sticks to Its Buy Rating for Neurogene (NGNE)](https://longbridge.com/en/news/286648209.md)
- [Needham Sticks to Their Buy Rating for WhiteFiber, Inc. (WYFI)](https://longbridge.com/en/news/286549506.md)